Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Historically, the company has been releasing figures that are above expectations.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • With an enterprise value anticipated at 4.26 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
GILEAD SCIENCES6.94%97 083
REGENERON PHARMACEUTICALS5.33%41 162
VERTEX PHARMACEUTICALS96.55%36 046
GENMAB-11.85%10 015
BLUEBIRD BIO INC199.68%8 449
EXELIXIS, INC.78.27%7 677
NEUROCRINE BIOSCIENCES, INC..83.39%6 232
TONGHUA DONGBAO PHARMACEUTI..8.44%6 159
BIOVERATIV INC0.00%5 785
JUNO THERAPEUTICS INC134.32%5 043
BIOCON LTD63.17%4 805
TESARO INC-37.63%4 561
BEIGENE LTD (ADR)209.19%4 268
PEPTIDREAM INC-38.24%4 018
HUALAN BIOLOGICAL ENGINEERI..--.--%3 953
BEIJING SL PHARMACEUTICAL C..--.--%3 519
More Results
Financials ($)
Sales 2017 25 816 M
EBIT 2017 15 661 M
Net income 2017 10 511 M
Debt 2017 12 742 M
Yield 2017 2,84%
P/E ratio 2017 9,56
P/E ratio 2018 12,46
EV / Sales 2017 4,25x
EV / Sales 2018 4,82x
Capitalization 97 083 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart GILEAD SCIENCES
Duration : Period : Day
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Duration : Period : Week
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders